Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
European Journal of Clinical Microbiology & Infectious Diseases
Published in: European Journal of Clinical Microbiology & Infectious Diseases 4/2012

Open Access 01-04-2012 | Review

The impact of diabetes on the pathogenesis of sepsis

Authors: G. C. K. W. Koh, S. J. Peacock, T. van der Poll, W. J. Wiersinga

Published in: European Journal of Clinical Microbiology & Infectious Diseases | Issue 4/2012

Login to get access

Abstract

Diabetes is associated with an increased susceptibility to infection and sepsis. Conflicting data exist on whether the mortality of patients with sepsis is influenced by the presence of diabetes, fuelling the ongoing debate on the benefit of tight glucose regulation in patients with sepsis. The main reason for which diabetes predisposes to infection appears to be abnormalities of the host response, particularly in neutrophil chemotaxis, adhesion and intracellular killing, defects that have been attributed to the effect of hyperglycaemia. There is also evidence for defects in humoral immunity, and this may play a larger role than previously recognised. We review the literature on the immune response in diabetes and its potential contribution to the pathogenesis of sepsis. In addition, the effect of diabetes treatment on the immune response is discussed, with specific reference to insulin, metformin, sulphonylureas and thiazolidinediones.
Literature
1.
Muller LMAJ, Gorter KJ, Hak E, Goudzwaard WL, Schellevis FG, Hoepelman AIM, Rutten GEHM (2005) Increased risk of common infections in patients with type 1 and type 2 diabetes mellitus. Clin Infect Dis 41:281–288PubMedCrossRef
2.
Shah BR, Hux JE (2003) Quantifying the risk of infectious diseases for people with diabetes. Diabetes Care 26:510–513PubMedCrossRef
3.
Finfer S, Chittock DR, Su SY-S, Blair D, Foster D, Dhingra V, Bellomo R, Cook D, Dodek P, Henderson WR, Hébert PC, Heritier S, Heyland DK, McArthur C, McDonald E, Mitchell I, Myburgh JA, Norton R, Potter J, Robinson BG, Ronco JJ (2009) Intensive versus conventional glucose control in critically ill patients. N Engl J Med 360:1283–1297PubMedCrossRef
4.
Stegenga ME, Vincent J-L, Vail GM, Xie J, Haney DJ, Williams MD, Bernard GR, van der Poll T (2010) Diabetes does not alter mortality or hemostatic and inflammatory responses in patients with severe sepsis. Crit Care Med 38:539–545PubMedCrossRef
5.
Restrepo BI (2007) Convergence of the tuberculosis and diabetes epidemics: renewal of old acquaintances. Clin Infect Dis 45:436–438PubMedCrossRef
6.
Joslin EP (1916) The treatment of diabetes mellitus: with observations upon the disease based upon one thousand cases. Lea & Febiger, Philadelphia
7.
Bertoni AG, Saydah S, Brancati FL (2001) Diabetes and the risk of infection-related mortality in the U.S. Diabetes Care 24:1044–1049PubMedCrossRef
8.
9.
Ali T, Meade K, Anari S, ElBadawey MR, Zammit-Maempel I (2010) Malignant otitis externa: case series. J Laryngol Otol 124:846–851PubMedCrossRef
10.
Carfrae MJ, Kesser BW (2008) Malignant otitis externa. Otolaryngol Clin North Am 41:537–549, viii–ixPubMedCrossRef
11.
Khaira A, Gupta A, Rana DS, Gupta A, Bhalla A, Khullar D (2009) Retrospective analysis of clinical profile prognostic factors and outcomes of 19 patients of emphysematous pyelonephritis. Int Urol Nephrol 41:959–966PubMedCrossRef
12.
Michaeli J, Mogle P, Perlberg S, Heiman S, Caine M (1984) Emphysematous pyelonephritis. J Urol 131:203–208PubMed
13.
Ahlering TE, Boyd SD, Hamilton CL, Bragin SD, Chandrasoma PT, Lieskovsky G, Skinner DG (1985) Emphysematous pyelonephritis: a 5-year experience with 13 patients. J Urol 134:1086–1088PubMed
14.
Cook DJ, Achong MR, Dobranowski J (1989) Emphysematous pyelonephritis. Complicated urinary tract infection in diabetes. Diabetes Care 12:229–232PubMedCrossRef
15.
Esper AM, Moss M, Martin GS (2009) The effect of diabetes mellitus on organ dysfunction with sepsis: an epidemiological study. Crit Care 13:R18PubMedCrossRef
16.
Thomsen RW, Hundborg HH, Lervang H-H, Johnsen SP, Sørensen HT, Schønheyder HC (2004) Diabetes and outcome of community-acquired pneumococcal bacteremia: a 10-year population-based cohort study. Diabetes Care 27:70–76PubMedCrossRef
17.
Tsai F-C, Huang Y-T, Chang L-Y, Wang J-T (2008) Pyogenic liver abscess as endemic disease, Taiwan. Emerg Infect Dis 14:1592–1600PubMedCrossRef
18.
Gregory JE, Golden A, Haymaker W (1943) Mucormycosis of the central nervous system: a report of three cases. Bull Johns Hopkins Hosp 73:405–419
19.
Mallis A, Mastronikolis SN, Naxakis SS, Papadas AT (2010) Rhinocerebral mucormycosis: an update. Eur Rev Med Pharmacol Sci 14:987–992PubMed
20.
Cheng AC, Currie BJ (2005) Melioidosis: epidemiology, pathophysiology, and management. Clin Microbiol Rev 18:383–416PubMedCrossRef
21.
Dooley KE, Chaisson RE (2009) Tuberculosis and diabetes mellitus: convergence of two epidemics. Lancet Infect Dis 9:737–746PubMedCrossRef
22.
Fine MJ, Smith MA, Carson CA, Mutha SS, Sankey SS, Weissfeld LA, Kapoor WN (1996) Prognosis and outcomes of patients with community-acquired pneumonia. A meta-analysis. JAMA 275:134–141PubMedCrossRef
23.
Thomsen RW, Hundborg HH, Lervang H-H, Johnsen SP, Schønheyder HC, Sørensen HT (2005) Diabetes mellitus as a risk and prognostic factor for community-acquired bacteremia due to enterobacteria: a 10-year, population-based study among adults. Clin Infect Dis 40:628–631PubMedCrossRef
24.
Kornum JB, Thomsen RW, Riis A, Lervang H-H, Schønheyder HC, Sørensen HT (2007) Type 2 diabetes and pneumonia outcomes: a population-based cohort study. Diabetes Care 30:2251–2257PubMedCrossRef
25.
Falagas ME, Alexiou VG, Giannopoulou KP, Siempos II (2007) Risk factors for mortality in patients with emphysematous pyelonephritis: a meta-analysis. J Urol 178:880–885, quiz 1129PubMedCrossRef
26.
Vincent J-L, Preiser J-C, Sprung CL, Moreno R, Sakr Y (2010) Insulin-treated diabetes is not associated with increased mortality in critically ill patients. Crit Care 14:R12PubMedCrossRef
27.
Michalia M, Kompoti M, Koutsikou A, Paridou A, Giannopoulou P, Trikka-Graphakos E, Clouva-Molyvdas P (2009) Diabetes mellitus is an independent risk factor for ICU-acquired bloodstream infections. Intensive Care Med 35:448–454PubMedCrossRef
28.
Tsai CL, Lee CC, Ma MH, Fang CC, Chen SY, Chen WJ, Chang SC, Mehta SH (2007) Impact of diabetes on mortality among patients with community-acquired bacteremia. J Infect 55:27–33PubMedCrossRef
29.
McAlister FA, Majumdar SR, Blitz S, Rowe BH, Romney J, Marrie TJ (2005) The relation between hyperglycemia and outcomes in 2,471 patients admitted to the hospital with community-acquired pneumonia. Diabetes Care 28:810–815PubMedCrossRef
30.
Kaplan V, Angus DC, Griffin MF, Clermont G, Scott Watson R, Linde-Zwirble WT (2002) Hospitalized community-acquired pneumonia in the elderly: age- and sex-related patterns of care and outcome in the United States. Am J Respir Crit Care Med 165:766–772PubMed
31.
Cooper G, Platt R (1982) Staphylococcus aureus bacteremia in diabetic patients. Endocarditis and mortality. Am J Med 73:658–662PubMedCrossRef
32.
Libert M, Elkholti M, Massaut J, Karmali R, Mascart G, Cherifi S (2008) Risk factors for meticillin resistance and outcome of Staphylococcus aureus bloodstream infection in a Belgian university hospital. J Hosp Infect 68:17–24PubMedCrossRef
33.
Carton JA, Maradona JA, Nuño FJ, Fernandez-Alvarez R, Pérez-Gonzalez F, Asensi V (1992) Diabetes mellitus and bacteraemia: a comparative study between diabetic and non-diabetic patients. Eur J Med 1:281–287PubMed
34.
Vardakas KZ, Siempos II, Falagas ME (2007) Diabetes mellitus as a risk factor for nosocomial pneumonia and associated mortality. Diabet Med 24:1168–1171PubMedCrossRef
35.
Graham BB, Keniston A, Gajic O, Trillo Alvarez CA, Medvedev S, Douglas IS (2010) Diabetes mellitus does not adversely affect outcomes from a critical illness. Crit Care Med 38:16–24PubMedCrossRef
36.
Gong MN, Thompson BT, Williams P, Pothier L, Boyce PD, Christiani DC (2005) Clinical predictors of and mortality in acute respiratory distress syndrome: potential role of red cell transfusion. Crit Care Med 33:1191–1198PubMedCrossRef
37.
Moss M, Guidot DM, Steinberg KP, Duhon GF, Treece P, Wolken R, Hudson LD, Parsons PE (2000) Diabetic patients have a decreased incidence of acute respiratory distress syndrome. Crit Care Med 28:2187–2192PubMedCrossRef
38.
Koh GCKW, Maude RR, Schreiber MF, Limmathurotsakul D, Wiersinga WJ, Wuthiekanun V, Lee SJ, Mahavanakul W, Chaowagul W, Chierakul W, White NJ, van der Poll T, Day NP, Dougan G, Peacock SJ (2011) Glyburide is anti-inflammatory and associated with reduced mortality in melioidosis. Clin Infect Dis 52:717–725PubMedCrossRef
39.
Watson RS, Angus DC (2002) Assessing outcomes in critical care. J Intensive Care Med 17:103–111CrossRef
40.
Schisterman EF, Cole SR, Platt RW (2009) Overadjustment bias and unnecessary adjustment in epidemiologic studies. Epidemiology 20:488–495PubMedCrossRef
41.
Hennekens CH, Buring JE (1987) Epidemiology in medicine. Lippincott Williams & Wilkins, Philadelphia, p 287
42.
Lassar O (1904) Ernährungstherapie bei Hautkrankheiten. Dermatologische Zeitschrift 11:189–209CrossRef
43.
Handmann E (1911) Über die Ursache der verminderten Resistenz des Diabetikers gegen Infektionen. Deutsches Archiv Für Klinische Medizin 102:1–14
44.
Da Costa JC Jr (1907) The opsonic index in diabetes mellitus: a preliminary record of the findings in 22 cases of glycosuria, with remarks on the technique of the opsonin test and on its clinical utility. Am J Med Sci 134:57–70CrossRef
45.
Balasoiu D, van Kessel KC, van Kats-Renaud HJ, Collet TJ, Hoepelman AI (1997) Granulocyte function in women with diabetes and asymptomatic bacteriuria. Diabetes Care 20:392–395PubMedCrossRef
46.
Pickup JC, Mattock MB, Chusney GD, Burt D (1997) NIDDM as a disease of the innate immune system: association of acute-phase reactants and interleukin-6 with metabolic syndrome X. Diabetologia 40:1286–1292PubMedCrossRef
47.
Myśliwska J, Zorena K, Bakowska A, Skuratowicz-Kubica A, Myśliwski A (1998) Significance of tumor necrosis factor alpha in patients with long-standing type-I diabetes mellitus. Horm Metab Res 30:158–161PubMedCrossRef
48.
Zozuliñska D, Majchrzak A, Sobieska M, Wiktorowicz K, Wierusz-Wysocka B (1999) Serum interleukin-8 level is increased in diabetic patients. Diabetologia 42:117–118PubMedCrossRef
49.
Yende S, van der Poll T, Lee M, Huang DT, Newman AB, Kong L, Kellum JA, Harris TB, Bauer D, Satterfield S, Angus DC (2010) The influence of pre-existing diabetes mellitus on the host immune response and outcome of pneumonia: analysis of two multicentre cohort studies. Thorax 65:870–877PubMedCrossRef
50.
Rao AK, Chouhan V, Chen X, Sun L, Boden G (1999) Activation of the tissue factor pathway of blood coagulation during prolonged hyperglycemia in young healthy men. Diabetes 48:1156–1161PubMedCrossRef
51.
Stegenga ME, van der Crabben SN, Levi M, de Vos AF, Tanck MW, Sauerwein HP, van der Poll T (2006) Hyperglycemia stimulates coagulation, whereas hyperinsulinemia impairs fibrinolysis in healthy humans. Diabetes 55:1807–1812PubMedCrossRef
52.
Geerlings SE, Brouwer EC, Van Kessel KC, Gaastra W, Stolk RP, Hoepelman AI (2000) Cytokine secretion is impaired in women with diabetes mellitus. Eur J Clin Invest 30:995–1001PubMedCrossRef
53.
Aird WC (2003) The role of the endothelium in severe sepsis and multiple organ dysfunction syndrome. Blood 101:3765–3777PubMedCrossRef
54.
Schuetz P, Yano K, Sorasaki M, Ngo L, St Hilaire M, Lucas JM, Aird W, Shapiro NI (2011) Influence of diabetes on endothelial cell response during sepsis. Diabetologia 54:996–1003PubMedCrossRef
55.
Neelamegham S, Taylor AD, Burns AR, Smith CW, Simon SI (1998) Hydrodynamic shear shows distinct roles for LFA-1 and Mac-1 in neutrophil adhesion to intercellular adhesion molecule-1. Blood 92:1626–1638PubMed
56.
Hentzen ER, Neelamegham S, Kansas GS, Benanti JA, McIntire LV, Smith CW, Simon SI (2000) Sequential binding of CD11a/CD18 and CD11b/CD18 defines neutrophil capture and stable adhesion to intercellular adhesion molecule-1. Blood 95:911–920PubMed
57.
Li J, Jin H-B, Sun Y-M, Su Y, Wang L-F (2010) KB-R7943 inhibits high glucose-induced endothelial ICAM-1 expression and monocyte-endothelial adhesion. Biochem Biophys Res Commun 392:516–519PubMedCrossRef
58.
Takami S, Yamashita S, Kihara S, Kameda-Takemura K, Matsuzawa Y (1998) High concentration of glucose induces the expression of intercellular adhesion molecule-1 in human umbilical vein endothelial cells. Atherosclerosis 138:35–41PubMedCrossRef
59.
Altannavch TS, Roubalová K, Kucera P, Andel M (2004) Effect of high glucose concentrations on expression of ELAM-1, VCAM-1 and ICAM-1 in HUVEC with and without cytokine activation. Physiol Res 53:77–82PubMed
60.
Andersen B, Goldsmith GH, Spagnuolo PJ (1988) Neutrophil adhesive dysfunction in diabetes mellitus; the role of cellular and plasma factors. J Lab Clin Med 111:275–285PubMed
61.
Delamaire M, Maugendre D, Moreno M, Le Goff MC, Allannic H, Genetet B (1997) Impaired leucocyte functions in diabetic patients. Diabet Med 14:29–34PubMedCrossRef
62.
Morigi M, Angioletti S, Imberti B, Donadelli R, Micheletti G, Figliuzzi M, Remuzzi A, Zoja C, Remuzzi G (1998) Leukocyte-endothelial interaction is augmented by high glucose concentrations and hyperglycemia in a NF-κB-dependent fashion. J Clin Invest 101:1905–1915PubMedCrossRef
63.
Taki H, Kashiwagi A, Tanaka Y, Horiike K (1996) Expression of intercellular adhesion molecules 1 (ICAM-1) via an osmotic effect in human umbilical vein endothelial cells exposed to high glucose medium. Life Sci 58:1713–1721PubMedCrossRef
64.
Park CW, Kim JH, Lee JH, Kim YS, Ahn HJ, Shin YS, Kim SY, Choi EJ, Chang YS, Bang BK (2000) High glucose-induced intercellular adhesion molecule-1 (ICAM-1) expression through an osmotic effect in rat mesangial cells is PKC-NF-κB-dependent. Diabetologia 43:1544–1553PubMedCrossRef
65.
Boyden S (1962) The chemotactic effect of mixtures of antibody and antigen on polymorphonuclear leucocytes. J Exp Med 115:453–466PubMedCrossRef
66.
Mowat A, Baum J (1971) Chemotaxis of polymorphonuclear leukocytes from patients with diabetes mellitus. N Engl J Med 284:621–627PubMedCrossRef
67.
Valerius NH, Eff C, Hansen NE, Karle H, Nerup J, Søeberg B, Sørensen SF (1982) Neutrophil and lymphocyte function in patients with diabetes mellitus. Acta Med Scand 211:463–467PubMedCrossRef
68.
Nelson RD, Quie PG, Simmons RL (1975) Chemotaxis under agarose: a new and simple method for measuring chemotaxis and spontaneous migration of human polymorphonuclear leukocytes and monocytes. J Immunol 115:1650–1656PubMed
69.
Tater D, Tepaut B, Bercovici JP, Youinou P (1987) Polymorphonuclear cell derangements in type I diabetes. Horm Metab Res 19:642–647PubMedCrossRef
70.
Bybee JD, Rogers DE (1964) The phagocytic activity of polymorphonuclear leukocytes obtained from patients with diabetes mellitus. J Lab Clin Med 64:1–13PubMed
71.
Bagdade JD, Root RK, Bulger RJ (1974) Impaired leukocyte function in patients with poorly controlled diabetes. Diabetes 23:9–15PubMed
72.
Bagdade JD (1976) Phagocytic and microbicidal function in diabetes mellitus. Acta Endocrinol Suppl (Copenh) 205:27–34
73.
Alexiewicz JM, Kumar D, Smogorzewski M, Klin M, Massry SG (1995) Polymorphonuclear leukocytes in non-insulin-dependent diabetes mellitus: abnormalities in metabolism and function. Ann Intern Med 123:919–924PubMed
74.
Davidson NJ, Sowden JM, Fletcher J (1984) Defective phagocytosis in insulin controlled diabetics: evidence for a reaction between glucose and opsonising proteins. J Clin Pathol 37:783–786PubMedCrossRef
75.
Dziatkowiak H, Kowalska M, Denys A (1982) Phagocytic and bactericidal activity of granulocytes in diabetic children. Diabetes 31:1041–1043PubMedCrossRef
76.
Tan JS, Anderson JL, Watanakunakorn C, Phair JP (1975) Neutrophil dysfunction in diabetes mellitus. J Lab Clin Med 85(1):26–33PubMed
77.
Bagdade JD, Nielson KL, Bulger RJ (1972) Reversible abnormalities in phagocytic function in poorly controlled diabetic patients. Am J Med Sci 263:451–456PubMedCrossRef
78.
Wilson RM, Reeves WG (1986) Neutrophil phagocytosis and killing in insulin-dependent diabetes. Clin Exp Immunol 63:478–484PubMed
79.
Shah SV, Wallin JD, Eilen SD (1983) Chemiluminescence and superoxide anion production by leukocytes from diabetic patients. J Clin Endocrinol Metab 57:402–409PubMedCrossRef
80.
Wykretowicz A, Wierusz-Wysocka B, Wysocki J, Szczepanik A, Wysocki H (1993) Impairment of the oxygen-dependent microbicidal mechanisms of polymorphonuclear neutrophils in patients with type 2 diabetes is not associated with increased susceptibility to infection. Diabetes Res Clin Pract 19:195–201PubMedCrossRef
81.
Sato N, Kashima K, Tanaka Y, Shimizu H, Mori M (1997) Effect of granulocyte-colony stimulating factor on generation of oxygen-derived free radicals and myeloperoxidase activity in neutrophils from poorly controlled NIDDM patients. Diabetes 46:133–137PubMedCrossRef
82.
Daoud AK, Tayyar MA, Fouda IM, Harfeil NA (2009) Effects of diabetes mellitus vs. in vitro hyperglycemia on select immune cell functions. J Immunotoxicol 6:36–41PubMedCrossRef
83.
Brinkmann V, Reichard U, Goosmann C, Fauler B, Uhlemann Y, Weiss DS, Weinrauch Y, Zychlinsky A (2004) Neutrophil extracellular traps kill bacteria. Science 303:1532–1535PubMedCrossRef
84.
Grinberg N, Elazar S, Rosenshine I, Shpigel NY (2008) β-Hydroxybutyrate abrogates formation of bovine neutrophil extracellular traps and bactericidal activity against mammary pathogenic Escherichia coli. Infect Immun 76:2802–2807PubMedCrossRef
85.
Hill HR, Augustine NH, Rallison ML, Santos JI (1983) Defective monocyte chemotactic responses in diabetes mellitus. J Clin Immunol 3:70–77PubMedCrossRef
86.
Geisler C, Almdal T, Bennedsen J, Rhodes JM, Kølendorf K (1982) Monocyte functions in diabetes mellitus. Acta Pathol Microbiol Immunol Scand C 90:33–37PubMed
87.
Katz S, Klein B, Elian I, Fishman P, Djaldetti M (1983) Phagocytotic activity of monocytes from diabetic patients. Diabetes Care 6:479–482PubMedCrossRef
88.
Nandy D, Janardhanan R, Mukhopadhyay D, Basu A (2011) Effect of hyperglycemia on human monocyte activation. J Investig Med 59:661–667PubMed
89.
Rattan V, Shen Y, Sultana C, Kumar D, Kalra VK (1996) Glucose-induced transmigration of monocytes is linked to phosphorylation of PECAM-1 in cultured endothelial cells. Am J Physiol 271:E711–E717PubMed
90.
Kitahara M, Eyre HJ, Lynch RE, Rallison ML, Hill HR (1980) Metabolic activity of diabetic monocytes. Diabetes 29:251–256PubMed
91.
Foss-Freitas MC, Foss NT, Donadi EA, Foss MC (2006) In vitro TNF-alpha and IL-6 production by adherent peripheral blood mononuclear cells obtained from type 1 and type 2 diabetic patients evaluated according to the metabolic control. Ann N Y Acad Sci 1079:177–180PubMedCrossRef
92.
MacCuish AC, Urbaniak SJ, Campbell CJ, Duncan LJ, Irvine WJ (1974) Phytohemagglutinin transformation and circulating lymphocyte subpopulations in insulin-dependent diabetic patients. Diabetes 23:708–712PubMed
93.
Speert DP, Silva J Jr (1978) Abnormalities of in vitro lymphocyte response to mitogens in diabetic children during acute ketoacidosis. Am J Dis Child 132:1014–1017PubMed
94.
Eibl N, Spatz M, Fischer GF, Mayr WR, Samstag A, Wolf HM, Schernthaner G, Eibl MM (2002) Impaired primary immune response in type-1 diabetes: results from a controlled vaccination study. Clin Immunol 103:249–259PubMedCrossRef
95.
Spatz M, Eibl N, Hink S, Wolf HM, Fischer GF, Mayr WR, Schernthaner G, Eibl MM (2003) Impaired primary immune response in type-1 diabetes. Functional impairment at the level of APCs and T-cells. Cell Immunol 221:15–26PubMedCrossRef
96.
Casey J, Sturm C Jr (1982) Impaired response of lymphocytes from non-insulin-dependent diabetics to staphage lysate and tetanus antigen. J Clin Microbiol 15:109–114PubMed
97.
Casey JI, Heeter BJ, Klyshevich KA (1977) Impaired response of lymphocytes of diabetic subjects to antigen of Staphylococcus aureus. J Infect Dis 136:495–501PubMedCrossRef
98.
Da Costa JC Jr, Beardsley EJG (1908) The resistance of diabetics to bacterial infection: a study of the opsonophagocytic properties of the blood in 74 cases of diabetes mellitus and related conditions. Am J Med Sci 136:361–373CrossRef
99.
Liberatore RDR Jr, Barbosa SFC, Das Graças Alkimin M, Bellinati-Pires R, Florido MPC, Isaac L, Kirschfink M, Grumach AS (2005) Is immunity in diabetic patients influencing the susceptibility to infections? Immunoglobulins, complement and phagocytic function in children and adolescents with type 1 diabetes mellitus. Pediatr Diabetes 6:206–212PubMedCrossRef
100.
Moen JK, Reimann HA (1933) Immune reactions in diabetes. Arch Intern Med 51:789–795CrossRef
101.
Richardson R (1933) Immunity in diabetes: influence of diabetes on the development of antibacterial properties in the blood. J Clin Invest 12:1143–1149PubMedCrossRef
102.
Fiçicioğlu C, Mikla S, Midilli K, Aydin A, Cam H, Erğin S (1995) Reduced immune response to hepatitis B vaccine in children with insulin dependent diabetes. Acta Paediatr Jpn 37:687–690PubMedCrossRef
103.
Pozzilli P, Arduini P, Visalli N, Sutherland J, Pezzella M, Galli C, Corradini SG, Biasio L, Gale EA, Andreani D (1987) Reduced protection against hepatitis B virus following vaccination in patients with type 1 (insulin-dependent) diabetes. Diabetologia 30:817–819PubMedCrossRef
104.
Alavian S-M, Tabatabaei SV (2010) The effect of diabetes mellitus on immunological response to hepatitis B virus vaccine in individuals with chronic kidney disease: a meta-analysis of current literature. Vaccine 28:3773–3777PubMedCrossRef
105.
Bouter KP, Diepersloot RJ, Wismans PJ, Gmelig Meyling FH, Hoekstra JB, Heijtink RA, van Hattum J (1992) Humoral immune response to a yeast-derived hepatitis B vaccine in patients with type 1 diabetes mellitus. Diabet Med 9:66–69PubMedCrossRef
106.
Douvin C, Simon D, Charles MA, Deforges L, Bierling P, Lehner V, Budkowska A, Dhumeaux D (1997) Hepatitis B vaccination in diabetic patients. Randomized trial comparing recombinant vaccines containing and not containing pre-S2 antigen. Diabetes Care 20:148–151PubMedCrossRef
107.
Brydak LB, Machala M (2000) Humoral immune response to influenza vaccination in patients from high risk groups. Drugs 60:35–53PubMedCrossRef
108.
Pozzilli P, Gale EA, Visalli N, Baroni M, Crovari P, Frighi V, Cavallo MG, Andreani D (1986) The immune response to influenza vaccination in diabetic patients. Diabetologia 29:850–854PubMedCrossRef
109.
Muszkat M, Friedman G, Dannenberg HD, Greenbaum E, Lipo M, Heymann Y, Zakay-Rones Z, Ben-Yehuda A (2003) Response to influenza vaccination in community and in nursing home residing elderly: relation to clinical factors. Exp Gerontol 38:1199–1203PubMedCrossRef
110.
Tamer A, Karabay O, Ekerbicer H, Tahtaci M, Selam B, Celebi H (2005) Impaired immunity against tetanus in type 2 diabetes. Med Sci Monit 11:CR580–CR584PubMed
111.
Kiliç D, Kaygusuz S, Saygun M, Cakmak A, Uzer H, Doğanci L (2003) Seroprevalence of tetanus immunity among noninsulin-dependent diabetes mellitus patients. J Diabetes Complications 17:258–263PubMedCrossRef
112.
Beam TR Jr, Crigler ED, Goldman JK, Schiffman G (1980) Antibody response to polyvalent pneumococcal polysaccharide vaccine in diabetics. JAMA 244:2621–2624PubMedCrossRef
113.
Mijovic CH, Fletcher JA, Bradwell AR, Barnett AH (1987) Low C4 levels in type 1 (insulin-dependent) diabetes. Diabetologia 30:824PubMedCrossRef
114.
Vergani D, Johnston C, B-Abdullah N, Barnett AH (1983) Low serum C4 concentrations: an inherited predisposition to insulin dependent diabetes? Br Med J (Clin Res Ed) 286:926–928CrossRef
115.
Jenhani F, Bardi R, Gorgi Y, Ayed K, Jeddi M (1992) C4 polymorphism in multiplex families with insulin dependent diabetes in the Tunisian population: standard C4 typing methods and RFLP analysis. J Autoimmun 5:149–160PubMedCrossRef
116.
Hernández-Mijares A, Jarabo-Bueno MM, López-Ruiz A, Solá-Izquierdo E, Morillas-Ariño C, Martínez-Triguero ML (2007) Levels of C3 in patients with severe, morbid and extreme obesity: its relationship to insulin resistance and different cardiovascular risk factors. Int J Obes (Lond) 31:927–932CrossRef
117.
Karlsson E, Shaat N, Groop L (2008) Can complement factors 5 and 8 and transthyretin be used as biomarkers for MODY 1 (HNF4A-MODY) and MODY 3 (HNF1A-MODY)? Diabet Med 25:788–791PubMedCrossRef
118.
Davin JC, Bouts AH, Krediet RT, van der Weel M, Weening RS, Groothoff J, Out TA (1997) IgG glycation and function during continuous ambulatory peritoneal dialysis. Nephrol Dial Transplant 12:310–314PubMedCrossRef
119.
Hostetter MK (1990) Handicaps to host defense. Effects of hyperglycemia on C3 and Candida albicans. Diabetes 39:271–275PubMedCrossRef
120.
Warren S (1930) Pathology of diabetes mellitus. Lea & Febiger, Philadelphia
121.
Rayfield EJ, Ault MJ, Keusch GT, Brothers MJ, Nechemias C, Smith H (1982) Infection and diabetes: the case for glucose control. Am J Med 72:439–450PubMedCrossRef
122.
King JT Jr, Goulet JL, Perkal MF, Rosenthal RA (2011) Glycemic control and infections in patients with diabetes undergoing noncardiac surgery. Ann Surg 253:158–165PubMedCrossRef
123.
Davis TME, Weerarathne T, Foong Y, Mason C, Davis WA (2005) Community-acquired infections in type 2 diabetic patients and their nondiabetic partners. The Fremantle Diabetes Study. J Diabetes Complications 19:259–263PubMedCrossRef
124.
Stegenga ME, van der Crabben SN, Blümer RME, Levi M, Meijers JCM, Serlie MJ, Tanck MWT, Sauerwein HP, van der Poll T (2008) Hyperglycemia enhances coagulation and reduces neutrophil degranulation, whereas hyperinsulinemia inhibits fibrinolysis during human endotoxemia. Blood 112:82–89PubMedCrossRef
125.
Stegenga ME, van der Crabben SN, Dessing MC, Pater JM, van den Pangaart PS, de Vos AF, Tanck MW, Roos D, Sauerwein HP, van der Poll T (2008) Effect of acute hyperglycaemia and/or hyperinsulinaemia on proinflammatory gene expression, cytokine production and neutrophil function in humans. Diabet Med 25:157–164PubMedCrossRef
126.
Dandona P, Aljada A, Mohanty P, Ghanim H, Hamouda W, Assian E, Ahmad S (2001) Insulin inhibits intranuclear nuclear factor κB and stimulates IκB in mononuclear cells in obese subjects: evidence for an anti-inflammatory effect? J Clin Endocrinol Metab 86:3257–3265PubMedCrossRef
127.
Hansen TK, Thiel S, Wouters PJ, Christiansen JS, Van den Berghe G (2003) Intensive insulin therapy exerts antiinflammatory effects in critically ill patients and counteracts the adverse effect of low mannose-binding lectin levels. J Clin Endocrinol Metab 88:1082–1088PubMedCrossRef
128.
129.
Leroux JP, Marchand JC, Hong Tuan Ha R, Cartier P (1975) The influence of insulin on glucose permeability and metabolism of human granulocytes. Eur J Biochem 58:367–373PubMedCrossRef
130.
Sbarra AJ, Karnovsky ML (1959) The biochemical basis of phagocytosis. I. Metabolic changes during the ingestion of particles by polymorphonuclear leukocytes. J Biol Chem 234:1355–1362PubMed
131.
Maianski NA, Geissler J, Srinivasula SM, Alnemri ES, Roos D, Kuijpers TW (2004) Functional characterization of mitochondria in neutrophils: a role restricted to apoptosis. Cell Death Differ 11:143–153PubMedCrossRef
132.
van den Berghe G, Wouters P, Weekers F, Verwaest C, Bruyninckx F, Schetz M, Vlasselaers D, Ferdinande P, Lauwers P, Bouillon R (2001) Intensive insulin therapy in the critically ill patients. N Engl J Med 345:1359–1367PubMedCrossRef
133.
van den Berghe G, Wilmer A, Hermans G, Meersseman W, Wouters PJ, Milants I, Van Wijngaerden E, Bobbaers H, Bouillon R (2006) Intensive insulin therapy in the medical ICU. N Engl J Med 354:449–461PubMedCrossRef
134.
Griesdale DEG, de Souza RJ, van Dam RM, Heyland DK, Cook DJ, Malhotra A, Dhaliwal R, Henderson WR, Chittock DR, Finfer S, Talmor D (2009) Intensive insulin therapy and mortality among critically ill patients: a meta-analysis including NICE-SUGAR study data. CMAJ 180:821–827PubMedCrossRef
135.
UK Prospective Diabetes Study (UKPDS) Group (1998) Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 352:854–865CrossRef
136.
Dandona P, Aljada A, Ghanim H, Mohanty P, Tripathy C, Hofmeyer D, Chaudhuri A (2004) Increased plasma concentration of macrophage migration inhibitory factor (MIF) and MIF mRNA in mononuclear cells in the obese and the suppressive action of metformin. J Clin Endocrinol Metab 89:5043–5047PubMedCrossRef
137.
138.
139.
Deakin AM, Payne AN, Blackwell GJ (1994) Role of potassium channels in the regulation of cytokine release from THP-1 cells. Inflamm Res 41:C188–C190
140.
Lamkanfi M, Mueller JL, Vitari AC, Misaghi S, Fedorova A, Deshayes K, Lee WP, Hoffman HM, Dixit VM (2009) Glyburide inhibits the Cryopyrin/Nalp3 inflammasome. J Cell Biol 187:61–70PubMedCrossRef
141.
Standen NB, Quayle JM, Davies NW, Brayden JE, Huang Y, Nelson MT (1989) Hyperpolarizing vasodilators activate ATP-sensitive K+ channels in arterial smooth muscle. Science 245:177–180PubMedCrossRef
142.
Landry DW, Oliver JA (1992) The ATP-sensitive K+ channel mediates hypotension in endotoxemia and hypoxic lactic acidosis in dog. J Clin Invest 89:2071–2074PubMedCrossRef
143.
Warrillow S, Egi M, Bellomo R (2006) Randomized, double-blind, placebo-controlled crossover pilot study of a potassium channel blocker in patients with septic shock. Crit Care Med 34:980–985PubMedCrossRef
144.
Morelli A, Lange M, Ertmer C, Broeking K, Van Aken H, Orecchioni A, Rocco M, Bachetoni A, Traber DL, Landoni G, Pietropaoli P, Westphal M (2007) Glibenclamide dose response in patients with septic shock: effects on norepinephrine requirements, cardiopulmonary performance, and global oxygen transport. Shock 28:530–535PubMed
145.
Mohanty P, Aljada A, Ghanim H, Hofmeyer D, Tripathy D, Syed T, Al-Haddad W, Dhindsa S, Dandona P (2004) Evidence for a potent antiinflammatory effect of rosiglitazone. J Clin Endocrinol Metab 89:2728–2735PubMedCrossRef
146.
Ghanim H, Garg R, Aljada A, Mohanty P, Kumbkarni Y, Assian E, Hamouda W, Dandona P (2001) Suppression of nuclear factor-kappaB and stimulation of inhibitor kappaB by troglitazone: evidence for an anti-inflammatory effect and a potential antiatherosclerotic effect in the obese. J Clin Endocrinol Metab 86:1306–1312PubMedCrossRef
147.
Lee S, Kim W, Kang KP, Moon S-O, Sung MJ, Kim DH, Kim HJ, Park SK (2005) Agonist of peroxisome proliferator-activated receptor-gamma, rosiglitazone, reduces renal injury and dysfunction in a murine sepsis model. Nephrol Dial Transplant 20:1057–1065PubMedCrossRef
148.
Wu W-T, Lee C-C, Lee C-J, Subeq Y-M, Lee R-P, Hsu B-G (2011) Rosiglitazone ameliorates endotoxin-induced organ damage in conscious rats. Biol Res Nurs 13:38–43PubMedCrossRef
149.
Stegenga ME, Florquin S, de Vos AF, van der Poll T (2009) The thiazolidinedione ciglitazone reduces bacterial outgrowth and early inflammation during Streptococcus pneumoniae pneumonia in mice. Crit Care Med 37:614–618PubMedCrossRef
150.
Zingarelli B, Cook JA (2005) Peroxisome proliferator-activated receptor-gamma is a new therapeutic target in sepsis and inflammation. Shock 23:393–399PubMedCrossRef
Metadata
Title
The impact of diabetes on the pathogenesis of sepsis
Authors
G. C. K. W. Koh
S. J. Peacock
T. van der Poll
W. J. Wiersinga
Publication date
01-04-2012
Publisher
Springer-Verlag
Published in
European Journal of Clinical Microbiology & Infectious Diseases / Issue 4/2012
Print ISSN: 0934-9723
Electronic ISSN: 1435-4373
DOI
https://doi.org/10.1007/s10096-011-1337-4

Other articles of this Issue 4/2012

European Journal of Clinical Microbiology & Infectious Diseases 4/2012 Go to the issue

Article

Fecal carriage of serotype K1 Klebsiella pneumoniae ST23 strains closely related to liver abscess isolates in Koreans living in Korea

Article

Gastrointestinal colonization with ESBL-producing Klebsiella in preterm babies—is vancomycin to blame?

Article

Lower catheter-related bloodstream infection in arterial than in venous femoral catheter

Article

Staphylococcus aureus nasal carriage is associated with serum 25-hydroxyvitamin D levels, gender and smoking status. The Tromsø Staph and Skin Study

Article

High prevalence of mec complex C and ccrC is independent of SCCmec type V in Staphylococcus haemolyticus

Article

Development of a polymerase chain reaction (PCR) test for the detection of virulent forms of Vibrio parahaemolyticus
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits